Advisor Group’s ETF Series Solutions Trust Range Cancer Therapeutics ETF CNCR Stock Holding History

Advisor Group’s Portfolio CNCR Stock Details CNCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	$31K	Hold	1,310	–	–	﹤0.01%	3711
2019 Q3	$25K	Hold	1,310	–	–	﹤0.01%	3810
2019 Q2	$27K	Buy	1,310 +1,000	+323%	+$20.6K	﹤0.01%	3770
2019 Q1	$6K	Buy	310 +67	+28%	+$1.41K	﹤0.01%	4583
2018 Q4	$5K	Hold	243	–	–	﹤0.01%	4500
2018 Q3	$6K	Sell	243 -267	-52%	-$6.56K	﹤0.01%	4500
2018 Q2	$12K	Buy	510 +310	+155%	+$8.36K	﹤0.01%	3986
2018 Q1	$6K	Hold	200	–	–	﹤0.01%	4321
2017 Q4	$5K	Sell	200 -420	-68%	-$10.6K	﹤0.01%	4383
2017 Q3	$17K	Hold	620	–	–	﹤0.01%	3642
2017 Q2	$14K	Hold	620	–	–	﹤0.01%	3722
2017 Q1	$15K	Buy	620 +520	+520%	+$12K	﹤0.01%	3536
2016 Q4	$2K	Hold	100	–	–	﹤0.01%	4205
2016 Q3	$3K	Hold	100	–	–	﹤0.01%	4054
2016 Q2	$2K	Buy	+100	New	+$2.28K	﹤0.01%	4070

Other funds holding CNCR

BCWM LLC Overland Park, Kansas $353M AUM 20.1% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

PAG

Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

AWA

Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Advisor Group's CNCR Position: Q4 2019 in Review

Advisor Group held its ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) position steady in Q4 2019 at 1,310 shares worth $31K. The position accounts for ﹤0.01% of the portfolio, ranked #3711.

Advisor Group first reported a position in CNCR in Q2 2016 and has held it in 15 quarters since. 23 funds tracked by Wall St. Rank hold CNCR as of Q4 2019.

Advisor Group held 1,310 shares of ETF Series Solutions Trust Range Cancer Therapeutics ETF worth $31K as of Q4 2019.
Advisor Group left its ETF Series Solutions Trust Range Cancer Therapeutics ETF share count unchanged in Q4 2019.
ETF Series Solutions Trust Range Cancer Therapeutics ETF made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #3711 holding.
Advisor Group first reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF in Q2 2016 and has held it in 15 quarters since.
23 funds tracked by Wall St. Rank held ETF Series Solutions Trust Range Cancer Therapeutics ETF as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.